The identification of clients that are crucial for the maintenance of each of the proposed hallmarks of cancer suggested that cancer itself might be an indication for an HSP90 inhibitor.

The combination of Hsp90 inhibitors with RAF or MEK inhibitors may achieve a better pathway inhibition in RAS and/or BRAF mutant tumors. This work will contribute significantly toward better patient ...